IP Library › Granted Patent US 8,187,804
Granted Patent B2
US 8,187,804 · App. 10/580,989 · Granted May 29, 2012

Specific marker Lmx1a on dopaminergic neurons

Assignee: Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,187,804
App. No.
10/580,989
Granted
May 29, 2012
Kind
B2
Abstract

The present invention identified Lmx1a genes, which are expressed in dopaminergic neurons at all differentiation stages, from proliferating dopaminergic neuron progenitor cells before cell cycle exit to cells after cell cycle exit. Lmx1a expression in cells can be used as an indicator when selecting cells suitable for transplantation therapy for neurodegenerative diseases such as Parkinson's disease, and is useful as a marker for screening agents involved in the induction of dopaminergic neuron differentiation.

Claims (33)

1. A method for detecting or selecting a dopaminergic neuron and/or a progenitor thereof, wherein the method comprises the step of contacting a cellular sample with a nucleic acid, wherein the nucleic acid comprises a sequence at least 80% identical to the complement of SEQ ID NO:13, 15, or 17, wherein the cellular sample comprises cells from the ventral midbrain of an animal.

2. A method for detecting or selecting a dopaminergic neuron and/or a progenitor cell thereof, wherein the method comprises the steps of:

(a) contacting a cellular sample that comprises cells from the ventral midbrain of an animal with a nucleic acid, wherein the nucleic acid comprises a sequence at least 80% identical to the complement of SEQ ID NO: 13, 15, or 17, and

(b) contacting the cellular sample with one or more polynucleotides or one or more antibodies, wherein the polynucleotide hybridizes under the washing conditions of 0.2×SSC and 0.1% SDS at 65° C. to a polynucleotide that encodes a protein selected from the group consisting of Lmx1b, Nurr1, En1, Ptx3, and TH, and wherein the antibody binds to the protein.

3. The method of claim 2 , which further comprises the step of:

(c) contacting a cellular sample with one or more polynucleotides or one or more antibodies, wherein the polynucleotide hybridizes under the washing conditions of 0.2×SSC and 0.1% SDS at 65° C. per wash to a polynucleotide that encodes a protein selected from DAT and ADH2 and wherein the antibody binds to the protein.

4. The method of claim 2 , wherein the protein is selected from the group consisting of Lmx1b, Nurr1, and En1.

5. A method for detecting or selecting a dopaminergic neuron and/or a progenitor cell thereof, wherein the method comprises the steps of:

(a) contacting a cellular sample that comprises cells from the ventral midbrain of an animal with a nucleic acid, wherein the nucleic acid comprises a sequence at least 80% identical to the complement of SEQ ID NO: 13, 15, or 17, and

(b) contacting the cellular sample with a polynucleotide that hybridizes with one or more polynucleotides or one or more antibodies, wherein the polynucleotide hybridizes under the washing conditions of 0.2×SSC and 0.1% SDS at 65° C. to a polynucleotide that encodes a protein selected from the group consisting of DAT and ADH2 and wherein the antibody binds to the protein.

6. A method for detecting or selecting a dopaminergic neuron and/or a progenitor cell thereof, wherein the method comprises the step of contacting a cellular sample with a polynucleotide comprising the complementary sequence of:

(1) the nucleotide sequence of SEQ ID NO: 13;

(2) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14;

(3) the nucleotide sequence of SEQ ID NO: 15 or 17; or

(4) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 or 18;

wherein the cellular sample comprises cells from the ventral midbrain of an animal.

7. A method for detecting or selecting a dopaminergic neuron and/or a progenitor cell thereof, wherein the method comprises the steps of:

(a) contacting a cellular sample that comprises cells from the ventral midbrain of an animal with a polynucleotide comprising the complementary sequence of:

(1) the nucleotide sequence of SEQ ID NO: 13;

(2) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14;

(3) the nucleotide sequence of SEQ ID NO: 15 or 17; or

(4) the nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 or 18; and

(b) contacting the cellular sample with one or more polynucleotides or one or more antibodies, wherein the complementary sequence of each of the polynucleotides encodes a protein selected from the group consisting of Lmx1b, Nurr1, En1, Ptx3, and TH, and wherein each of the antibodies binds to the protein selected from said group.

8. The method of claim 7 , which further comprises the step of:

(c) contacting the cellular sample with one or more polynucleotides or one or more antibodies, wherein the complementary sequence of each of the polynucleotides encodes a protein selected from DAT and ADH2, and wherein each of the antibodies binds to the protein selected from said group.

9. The method of claim 7 , wherein the protein in step (b) is selected from the group consisting of Lmx1b, Nurr1, and En1.

10. A method for detecting or selecting a dopaminergic neuron and/or a progenitor cell thereof, wherein the method comprises the steps of:

(a) contacting a cellular sample that comprises cells from the ventral midbrain of an animal with a polynucleotide comprising the complementary sequence of:

(1) the nucleotide sequence of SEQ ID NO: 13;

(2) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 14;

(3) the nucleotide sequence of SEQ ID NO: 15 or 17; or

(4) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 16 or 18; and

(b) contacting the cellular sample with one or more polynucleotides or one or more antibodies, wherein the complementary sequence of each of the polynucleotides encodes a protein selected from the group consisting of DAT and ADH2, and wherein each of the antibodies binds to the protein selected from said group.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019265/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2007
From: ONO, YUICHI; NAKAGAWA, YASUKO; NAKATANI, TOMOYA
To: EISAI CO., LTD.
Reel/Frame 019095/0837 →
Priority Claims (1)
JP 2003-395493 · Nov 26, 2003 · national
Continuity (1)
Related Publication 20070254281A1 · Nov 1, 2007